Drug Trial Radar · NCT04678908
A Study of Injection HB0025 in Patients With Advanced Solid Tumors
Last checked: Nov 19, 2026Latest source record: Jun 1, 2022 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
154
Planned (sponsor's estimate)
Start
Mar 10, 2021
Primary completion
Feb 2, 2024
Study completion May 23, 2024
Sponsor
- Lead sponsor
- Huabo Biopharm Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Dec 22, 2020
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Sequential
- Masking
- None
- Primary purpose
- Basic science
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a multicenter, open-label, dose escalation and expansion study. During the study, subjects will be evaluated for safety, toxicity, tolerability, PK/PD, immunogenicity, biomarkers, and antitumor activity of HB0025. The phase I study will enroll up to 154 subjects with advanced solid tumors who have progressed on or after standard of care therapy and for whom there is no further treatment available that in the judgement of the patient's physician would be beneficial. One cycle is defined as 28 days.
Conditions
- Tumor, Subjects
Interventions
HB0025Drug
Patients will be assigned to dose regimens in the order of enrollment, and they will receive their assigned fixed dose of HB0025 via intravenous infusion.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Safety assessment in dose-escalation phaseTime frame: 240 Days
- Safety assessment in dose-escalation phaseTime frame: 240 Days
- Efficacy assessment in dose-expansion phaseTime frame: Up to 24 Moths
Locations
6 sites in 2 countries. Site status is shown where the registry gives one.
NEXT Oncology
San Antonio, Texas · Recruiting
The First Affiliated Hospital of Bengbu Medical College
Bengbu, Anhui, China · Recruiting
Central Hospital Affiliated to ShanDong First Medical University
Jinan, Shandong, China · Recruiting
Qilu Hospital of Shandong University
Jinan, Shandong, China · Recruiting
Linyi Cancer Hospital
Linyi, Shandong, China · Recruiting
Fudan University Shanghai Cancer Center
Shanghai, Shanghai Municipality, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.